The 6 best GLP-1 telehealth programs of 2026
This category has never been more competitive, and that is very good news if you are the one buying. Six programs now compete on price, on speed, on formulary and on service — and the gap between the best of them and where this market was two years ago is enormous. Below, all six ranked on what can actually be verified: published outcome data, third-party ratings, live pricing and what happens when you ask for your money back.
1. Found
Found is the standout here and it is not especially close. It is the only program on this page with a peer-reviewed, published outcome study — 66,094 patients in Obesity Science & Practice (2025) — and the only one that will bill your insurance for the medication and hand you FDA-approved brand-name Wegovy, Zepbound, Ozempic or Mounjaro rather than a compounded substitute. If your plan covers GLP-1s, that combination is worth more than every other difference on this page put together.
- Real published results. In the study cohort, GLP-1 users averaged 13.9% body weight lost at twelve months, and 82.9% of members maintained their loss over the year. Nobody else here has published anything comparable.
- The widest formulary in the category — Found describes 13 medications in more than 60 combinations, spanning branded GLP-1s, compounded options and non-GLP-1 alternatives, so a plan can actually be changed rather than abandoned.
- Insurance navigation in all 50 states, with most members reporting under $30 per visit once coverage is applied.
- The best-loved app of the six — 4.7 out of 5 from about 8,700 App Store ratings — and a BBB A+ with accreditation.
- Worth knowing: there is no money-back guarantee, and a cancellation fee can apply if you leave part-way through a six-month term. Read the term length at checkout before you commit.
2. Direct Meds
If you judge a company by what its actual customers say at scale, Direct Meds runs away with this page. 4.6 out of 5 from 7,779 Trustpilot reviews is not just the highest score here — it is roughly twelve times the review volume of any other program we compared, which makes it the hardest number on this page to dismiss. It is also the fastest: provider review within hours and 1–2 day fulfilment, with shipping included.
- The strongest third-party review base of the six, by a wide margin, on both score and volume.
- Genuinely fast. Provider review within hours rather than days, 1–2 day fulfilment and free shipping — the shortest published path from signing up to injecting.
- A sublingual option as well as injectable, which matters more than it sounds if needles are the thing stopping you.
- Fast-growing and Utah-based, with company-reported growth from $8M to $80M in revenue between 2024 and 2025 and 125,000+ patients served.
- Worth knowing: the FDA sent Direct Meds a warning letter on 9 September 2025 over its marketing language, and its BBB file shows 258 complaints in three years. Promotional pricing also varies by landing page — confirm the ongoing price, not just the first month.
3. RemedyMeds
RemedyMeds is the most complete package on this page and the only one that includes your bloodwork. Labs through Quest, BioReference or LabCorp at no extra cost, clinician review inside 24 hours, free 48-hour cold-chain FedEx delivery and support seven days a week — that is a real service business, not a checkout page with a prescription attached. It is also the biggest: RemedyMeds acquired Thirty Madison (Keeps, Nurx, Cove) in an all-stock deal reported at over $500M in September 2025.
- Labs are included — the only program here where baseline bloodwork is part of the price rather than an errand you run yourself.
- Best switching experience in the category. RemedyMeds keeps you at your current dose from day one rather than restarting you at the bottom of the titration ladder, which is the single most annoying part of changing providers.
- Independently vetted twice over — Forbes Health scored the platform 4.3 out of 5, and it was accepted onto the Health-E Commerce FSA/HSA Store marketplace in October 2025, which involves third-party vendor review rather than a self-declared claim.
- A microdose tier at a lower price point for people who want to start gently, alongside standard semaglutide and tirzepatide.
- Worth knowing: the FDA sent RemedyMeds a warning letter on 9 September 2025 over its marketing language, its BBB file shows 428 complaints and an F grade, and the widely-advertised “$120 off” has been running continuously since at least December 2025 — treat it as the standard price, not a deadline.
4. bmiMD
bmiMD is the price floor of this entire category and it is not shy about it: $99 a month for compounded semaglutide on a twelve-month term, with the provider visit included and no separate membership fee. The detail that makes that price genuinely interesting rather than merely cheap is that it does not rise as your dose rises — on most competing plans, month eight costs considerably more than month one.
- $99/month, and flat at every dose. Nobody else on this page verified lower, and the no-dose-escalation pricing is the part that actually saves money over a full year.
- The most specific quality disclosure of the six. bmiMD publishes its testing regime — potency within ±10%, USP 797 sterility, pH and USP 85 endotoxin testing — where most competitors publish adjectives.
- It tells the truth about compounding on its own website, stating plainly that compounded medications are not FDA-approved. That is rarer in this category than it should be, and it counts.
- Buy-now-pay-later financing is offered, which no other program here advertises — useful if the twelve-month term is the obstacle.
- Worth knowing: the lowest rate needs $1,188 up front, the money-back guarantee only covers you if you are not approved, and bmiMD carries the weakest BBB file of the three brands we review in depth (C+, not accredited).
5. TrimRx
TrimRx is the most straightforward proposition here, and for a lot of people that is exactly the appeal: one flat all-inclusive monthly price, no membership fee stacked on top, no insurance paperwork, and everything you need to inject arriving in a single cold-chain shipment. It is also BBB-accredited, which of the six is a distinction only Found otherwise shares.
- All-inclusive flat pricing — medication, consultation and supplies in one number, with no membership fee bolted on.
- BBB accreditation since 18 June 2025, a voluntary standards commitment that four of the six programs here have not made.
- Everything arrives in the box — medication, syringes, needles, alcohol pads and a sharps container, cold-chain tracked, so there is no separate pharmacy trip on day one.
- Pricing has moved in customers’ favour — trimrx.com listed $179/month for compounded semaglutide when we checked, below the figures most comparison sites still quote.
- Worth knowing: TrimRx has published no outcome data of any kind, its BBB profile has no letter grade yet, and there is an active customer petition alleging delivery and refund problems. Orders also become non-refundable once intake is submitted.
6. MEDVi
MEDVi has the most format flexibility on this page: it is one of the few programs here offering a daily oral tablet as well as a weekly injection, and it runs a separate low-cost membership tier that routes to branded Wegovy or Zepbound. It is also large and profitable — the New York Times verified $401M in revenue and 250,000 customers for 2025. We rank it sixth anyway, and the reasons are important enough to state plainly rather than bury.
- Oral tablets and injections, semaglutide or tirzepatide — the widest set of delivery formats of any program on this page.
- A branded route exists via a separate low-cost membership tier, for people who want Wegovy or Zepbound rather than a compounded product.
- Serious scale, independently verified: $401M revenue, $65M profit and roughly a quarter of a million customers in 2025.
- Why it is last, and this is not a small thing: a May 2025 investigation documented AI-generated before-and-after photos, fabricated patient testimonials and fabricated doctor endorsements in MEDVi's marketing, and the New York Times later appended an editor's note to its own profile of the company.
- Also worth knowing: MEDVi received an FDA warning letter dated 20 February 2026, holds a BBB F grade with 662 complaints, and is not itself a pharmacy or a medical practice — clinical care and dispensing are contracted out to third parties.
All six, side by side
| Program | Compounded from | Ongoing | Insurance | Standout strength | Read the terms for |
|---|---|---|---|---|---|
| 1. Found | $99/mo | $99/mo flat | Yes | Peer-reviewed outcomes; branded meds | Term length and cancellation terms |
| 2. Direct Meds | $197 promo | $297/mo | No | Trustpilot 4.6 from 7,779 reviews | Ongoing price; billing cadence |
| 3. RemedyMeds | $179 first mo | $299/mo | No | Labs included; same-dose switching | Cancellation; the evergreen “$120 off” |
| 4. bmiMD | $99/mo | $99–$129 by term | No | Cheapest verified; flat at every dose | $1,188 up front; guarantee scope |
| 5. TrimRx | $179/mo | $179/mo | No | All-inclusive kit; BBB accredited | Non-refundable after intake |
| 6. MEDVi | $179 first mo | $299/mo | No | Oral tablet option; branded tier | BBB record; marketing claims |
How to choose in about five minutes
Step one: call your insurer, not the telehealth company. Ask whether your plan covers GLP-1 medication for weight management and what the copay is. This one answer decides most of the question. If it is yes, Found is the only program here that can use it, and a $30 copay on branded Zepbound beats a $99 compounded plan on cost and on regulatory footing simultaneously.
Step two: if you are paying cash, decide what you are optimising for. Lowest total cost over a year is bmiMD. Weight of customer evidence is Direct Meds. Most included in the price — labs, cold-chain shipping, seven-day support — is RemedyMeds. Simplest single flat number is TrimRx. These are genuinely different products and there is no wrong answer among them.
Step three: decide how you feel about compounded medication. Compounded semaglutide and tirzepatide are not FDA-approved and the FDA has not reviewed them for safety, effectiveness or quality. The shortages that made routine compounding lawful were declared resolved in December 2024 and February 2025, and the grace period ended in May 2025. Narrow 503A exceptions remain — a documented allergy to an inactive ingredient, or a genuinely non-standard dose — but cost saving alone is not one of them. On 30 April 2026 the FDA proposed removing all three molecules from the 503B Bulks List. Whichever program you pick, do not assume a twelve-month prepaid compounded plan will look the same in twelve months.
The FDA letters, in plain English
Three of the six programs on this page — Direct Meds, RemedyMeds and MEDVi — have received an FDA warning letter. We have said so in each card and we are saying so again here, because a roundup that quietly leaves this out is not worth reading.
What the letters are actually about matters, though. All three were part of a wave of more than fifty letters the FDA sent to telehealth marketers in this category, and in each case the agency objected to how the product was advertised — specifically, marketing that presented a compounded product as though it were equivalent to an FDA-approved branded drug. They are letters about advertising copy. They are not findings that anyone was harmed, and they are not recalls.
The practical takeaway for you is narrower than it sounds: a compounded GLP-1 is not the branded drug, whatever a landing page implies, and you should price and judge it as its own thing. If that distinction matters to you, that is exactly the argument for Found, which supplies the FDA-approved branded products directly.
How we ranked, and what we could not verify
Independent editorial coverage of this category is close to non-existent. What fills search results instead is affiliate content, paid press releases reprinted as news, and “reviews” written by competitors. That is why this page cites Trustpilot, ConsumerAffairs, the BBB, a peer-reviewed journal, the companies’ own live pages and named FDA documents, and almost nothing else. Published outcome data outranks a rating; a rating outranks a company claim; a company claim on its own gets reported as a company claim.
Things we could not establish, listed so you know where the edges are: which of Found’s several published price structures a real 2026 signup lands on; TrimRx’s current Trustpilot review count, where sources disagree sharply; MEDVi’s live pricing, because its own pricing page returned unrendered template placeholders when we checked, so the figures above are third-party; and the recipient list for the 30 FDA warning letters announced on 3 March 2026, which was never published — so no claim can honestly be made about which companies were or were not on it.
Frequently asked questions
Which GLP-1 telehealth program is best?
Found, for most people, and clearly so if you have commercial insurance that covers GLP-1s — it is the only one of the six that bills insurance, the only one that supplies FDA-approved brand-name medication directly, and the only one with a peer-reviewed published outcome study behind it. If you are paying cash, Direct Meds has the strongest verified customer review base and bmiMD has the lowest verified price.
Which one is cheapest?
bmiMD, at $99 per month for compounded semaglutide on a 12-month prepaid term ($1,188 up front), with no separate membership fee and the same price at every dose. Found also starts at $99/month for its compounded plans and holds that price as your dose increases.
Which one has the best customer reviews?
Direct Meds, at 4.6 out of 5 from 7,779 Trustpilot reviews — both the highest score and, by a wide margin, the largest review base of the six. Found holds the best app rating at 4.7 out of 5 from about 8,700 App Store ratings, and the only A+ BBB grade on this page.
Do any of them take insurance?
Only Found bills insurance for the medication, and it does so in all 50 states; members with coverage commonly report paying under $30 per visit. Found's own membership fee is not covered. The other five are cash-pay, though all of them accept HSA and FSA cards.
Which ones include lab work?
RemedyMeds is the only one of the six that includes baseline bloodwork in the price, through Quest, BioReference or LabCorp. With every other program you arrange and pay for labs yourself.
Can I get an oral GLP-1 instead of an injection?
Yes, from four of the six. MEDVi offers compounded semaglutide and tirzepatide as daily oral tablets, Direct Meds offers a sublingual semaglutide, TrimRx offers an oral semaglutide at around $179 a month, and Found can prescribe Rybelsus, the FDA-approved oral semaglutide tablet. RemedyMeds and bmiMD are injection-only.
Is compounded semaglutide the same as Ozempic or Wegovy?
No. Compounded semaglutide is not FDA-approved. The FDA has not reviewed compounded products for safety, effectiveness or quality, and they are not the branded products. The FDA has sent multiple waves of warning letters to telehealth marketers in this category since September 2025, and several of those letters concern exactly this equivalence claim.
How is this page paid for?
The Weight Verdict earns a referral fee when a reader signs up through one of the links on this page. That is disclosed at the top and bottom of every page. The ranking above is based on published outcome data, third-party ratings, verified pricing and published terms — not on what each program pays.
Sources
- Clark et al., “Real-world weight loss outcomes in a telehealth weight-management programme”, Obesity Science & Practice, 2025 (DOI 10.1002/osp4.70036), n = 66,094.
- Trustpilot listings for joinfound.com, directmeds.com, trimrx.com and bmimd.com (ratings, review counts, response rates).
- ConsumerAffairs listing for MEDVi (2,185 reviews) and ConsumerAffairs listing for RemedyMeds.
- Better Business Bureau profiles for Found, Direct Meds LLC, Remedy Meds LLC, MEDVi LLC, TrimRx and MEDCCM, Inc. d/b/a bmiMD.
- Forbes Health provider assessment of RemedyMeds (platform score 4.3 / 5).
- Live pricing checks on joinfound.com, directmeds.com, remedymeds.com, bmimd.com and trimrx.com, 27 July 2026.
- Apple App Store and Google Play listings for the Found app.
- Fierce Healthcare, Axios and MobiHealthNews reporting on the RemedyMeds acquisition of Thirty Madison, September 2025.
- The New York Times profile of MEDVi and its subsequent editor’s note; Futurism investigation into MEDVi marketing imagery, May 2025.
- FDA warning letters to Direct Meds and Remedy Meds (9 September 2025, MARCS-CMS 716830) and to MEDVi (20 February 2026, #721455).
- FDA proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List, 30 April 2026.
- FDA shortage resolution notices for semaglutide (December 2024) and tirzepatide (February 2025).
Figures on this page were checked on 27 July 2026. Prices, promotions and third-party ratings change frequently — always confirm the current price on the provider’s own checkout before you pay.